{"organizations": [], "uuid": "b9799e91a9bf51709de2e01a93ec4d9fe939bb80", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-glenmark-pharma-enters-exclusive-c/brief-glenmark-pharma-enters-exclusive-collaboration-agreement-with-scd-pharmaceuticals-idUSFWN1QB0XX", "country": "US", "domain_rank": 408, "title": "BRIEF-Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T19:54:00.000+02:00", "replies_count": 0, "uuid": "b9799e91a9bf51709de2e01a93ec4d9fe939bb80"}, "author": "", "url": "https://www.reuters.com/article/brief-glenmark-pharma-enters-exclusive-c/brief-glenmark-pharma-enters-exclusive-collaboration-agreement-with-scd-pharmaceuticals-idUSFWN1QB0XX", "ord_in_thread": 0, "title": "BRIEF-Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals", "locations": [], "entities": {"persons": [], "locations": [{"name": "south korea", "sentiment": "none"}], "organizations": [{"name": "scd pharmaceuticals february", "sentiment": "negative"}, {"name": "reuters) - glenmark pharmaceuticals ltd", "sentiment": "none"}, {"name": "scd pharmaceuticals reuters staff", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 5:55 PM / in 25 minutes BRIEF-Glenmark Pharma Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals Reuters Staff Feb 21 (Reuters) - Glenmark Pharmaceuticals Ltd: * GLENMARK PHARMACEUTICALS - ‚ÄçENTERED INTO EXCLUSIVE DEAL WITH SAM CHUN DANG PHARM * GLENMARK PHARMACEUTICALS SAYS PRODUCTS FROM AGREEMENT WILL BE DEVELOPED AND MANUFACTURED BY SCD IN SOUTH KOREA * GLENMARK PHARMACEUTICALS SAYS WILL SEEK ALL MARKET AUTHORIZATIONS AND COMMERCIALIZE PRODUCTS FROM AGREEMENT IN NORTH AMERICA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T19:54:00.000+02:00", "crawled": "2018-02-21T20:25:37.004+02:00", "highlightTitle": ""}